This discovery holds significant promise for the development of cancer vaccines or T-cell-based immunotherapies, particularly in tumors with high expression of HERVs from the HML-2 family, such as triple-negative breast cancer cases in prostate cancer, HML-2 expression is higher than in benign tissues, and it correlates with tumor development and metastasis [96,106]. This evidence concerns the gene CLEC10A and prostate cancer.